Independent predictors for CDAI at week 52 in multivariable analysis
| Abatacept | Tocilizumab | |||||
|---|---|---|---|---|---|---|
| Regression coefficient | Regression coefficient | |||||
| Standardised | Unstandardised | p Value | Standardised | Unstandardised | p Value | |
| Age | −0.01 | 0.96 | −0.02 | 0.83 | ||
| Sex (male) | 0.12 | 0.18 | 0.10 | 0.27 | ||
| Disease duration | 0.05 | 0.58 | −0.06 | 0.54 | ||
| Prior use of biological agents | 0.13 | 0.12 | 0.24 | 4.91 | 0.01 | |
| MTX use | −0.01 | 0.94 | −0.11 | 0.22 | ||
| CRP (at baseline) | 0.01 | 0.95 | −0.18 | 0.05 | ||
| RF titre (at baseline) | −0.21 | −0.01 | 0.02 | 0.15 | 0.11 | |
| MMP-3 (at baseline) | −0.08 | 0.35 | −0.05 | 0.57 | ||
| SDAI (at baseline) | 0.54 | 0.46 | <0.001 | 0.03 | 0.77 | |
| HAQ-DI (at baseline) | 0.02 | 0.82 | 0.39 | 4.69 | <0.001 | |
Significant results are shown in bold.
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index.